Innovus Pharmaceuticals Announces the Official Launch of Sensum+(R) in Morocco by its Partner Ovation Pharma with an Initial Order of Approximately 240,000 Doses

SAN DIEGO, CA / ACCESSWIRE / May 12, 2015 / Innovus Pharmaceuticals, Inc., (“Innovus Pharma” or the “Company) www.innovuspharma.com (OTCQB: INNV)
a company focusing on the commercialization of over-the-counter (“OTC”)
and consumer products for men’s and women’s health, vitality and
respiratory diseases announced today that its partner Ovation Pharma
officially launched Sensum+(R) in Morocco. The launch took place during
the annual meeting of the Moroccan Association of Urology in Rabat from
May 07 to May 09. Ovation Pharma launched the product with an initial
order of approximately 240,000 doses. Sensum+(R) is currently promoted by
Ovation Pharma sales force and will be placed behind the counter and
dispensed with a physician prescription.

“This is our third product launched in Morocco, following the launch
of our products Zestra(R) and Zestra Glide(R) by our partner Sothema Labs
earlier in the year. Sensum+ is a unique product for a large indication
and we look forward to a successful market penetration by our partner
Ovation Pharma,” said Dr. Bassam Damaj, President & Chief Executive
Officer of Innovus Pharma.

On September 9, 2013 Innovus Pharma granted to Ovation Pharma an
exclusive license to market and sell Innovus Pharma’s topical treatment to increase penile sensitivity in Morocco. Under the agreement, Innovus
is eligible to receive up to approximately $11.2 million U.S. dollars
upon and subject to the achievement of sales milestones based on
cumulative supplied units of the licensed products in the Territory plus
a pre-negotiated transfer price per unit and minimum orders.

About Sensum+(R) and Reduced Penile Sensitivity

Sensum+(R) is a patented blend of essential oils and natural botanicals
including rose oil, sweet almond oil, cinnamon bark oil, and other
extracts. The main ingredient of Sensum+(R) (cinnamon oil) works by
activating the Transient Receptor Potential A1 (TRPA-1) channels
responsible for the heat and cold sensation of the skin and results in
an increase of sensation that current users welcome and appreciate. The
safety and efficacy of Sensum+(R) was evaluated in 2 post marketing survey
studies in circumcised and non-circumcised men. A total of 382 men used
Sensum+(R) twice daily for fourteen consecutive days followed by once
daily for 8 weeks and as needed thereafter.

For more information visit www.sensumplus.com.

About Innovus Pharmaceuticals, Inc.

Headquartered in San Diego, Innovus Pharma is an emerging leader in
OTC and consumer products for men’s and women’s health and vitality. The
Company generates revenues from its lead products Zestra(R) for female
arousal and EjectDelay(R) for premature ejaculation and has a total of
five marketed products in this space, including Sensum+(R) for the
indication of reduced penile sensitivity, (for sales outside the U.S.
only), Zestra Glide(R), Vesele(R) for promoting sexual and cognitive health,
Androferti(R) (in the US and Canada) to support overall male reproductive
health and sperm quality, and FlutiCare(TM) OTC for Allergic Rhinitis.

For more information, go to www.innovuspharma.com, www.zestra.com; www.ejectdelay.com; www.myvesele.com; www.sensumplus.com; www.myadroferti.com.

Innovus Pharma’s Forward-Looking Safe Harbor

Statements under the Private Securities Litigation Reform Act, as
amended: with the exception of the historical information contained in
this release, the matters described herein contain forward-looking
statements that involve risks and uncertainties that may individually or
mutually impact the matters herein described for a variety of reasons
that are outside the control of the Company, including, but not limited
to, receiving patent protection for any of its products, receiving
approval or to be compliant with the requirements of any relevant
regulatory authority relating to such products such as Sensum+(R), to
successfully commercialize such products in the Morocco and in other
countries and regions, and to achieve its other development,
commercialization, financial and staffing objectives. Readers are
cautioned not to place undue reliance on these forward-looking
statements as actual results could differ materially from the
forward-looking statements contained herein. Readers are urged to read
the risk factors set forth in the Company’s most recent annual report on
Form 10-K, subsequent quarterly reports filed on Form 10-Q and other
filings made with the SEC. Copies of these reports are available from
the SEC’s website or without charge from the Company.

Contact:

Kevin Holmes
Chesapeake Group
info@chesapeakegp.com
T: 410-825-3930

SOURCE: Innovus Pharmaceuticals, Inc. 

ReleaseID: 428769